- Home
- MDGL
as 03-31-2025 4:00pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 7.5B | IPO Year: | N/A |
| Target Price: | $354.75 | AVG Volume (30 days): | 338.0K |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.90 | EPS Growth: | N/A |
| 52 Week Low/High: | $189.00 - $377.46 | Next Earning Date: | 05-06-2025 |
| Revenue: | $180,133,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 217.05% | Revenue Growth (next year): | 84.73% |
Stock Insider Trading Activity of Madrigal Pharmaceuticals Inc. (MDGL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CRAVES FRED B | MDGL | Director | Mar 12 '25 | Sell | $328.89 | 15,470 | $5,082,479.62 | 350,076 | |
| Dier Mardi | MDGL | SVP and CFO | Mar 10 '25 | Sell | $323.04 | 258 | $83,344.32 | 10,440 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Mar 5 '25 | Sell | $340.42 | 14,113 | $4,817,103.60 | 16,941 | |
| Huntsman Carole | MDGL | Chief Commercial Officer | Mar 3 '25 | Sell | $323.86 | 1,834 | $597,839.68 | 9,467 | |
| Dier Mardi | MDGL | SVP and CFO | Mar 3 '25 | Sell | $324.71 | 1,961 | $637,248.06 | 10,440 | |
| Kelley Shannon T | MDGL | General Counsel | Mar 3 '25 | Sell | $335.00 | 415 | $139,025.00 | 7,290 | |
| Waltermire Robert E. | MDGL | Senior VP, Chief Pharma Dev. | Feb 28 '25 | Sell | $341.27 | 1,227 | $418,488.05 | 16,941 | |
| BATE KENNETH | MDGL | Director | Feb 27 '25 | Sell | $355.92 | 20,000 | $7,128,758.96 | 2,128 | |
| Daly James M | MDGL | Director | Feb 27 '25 | Sell | $347.75 | 15,470 | $5,375,125.55 | 1,912 | |
| Taub Rebecca | MDGL | Pres., R&D, and CMO | Jan 24 '25 | Sell | $335.24 | 648 | $217,235.52 | 456,662 |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Is Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?
Simply Wall St.
3 days ago
Exploring 3 High Growth Tech Stocks in the US Market
Insider Monkey
14 days ago
Madrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to Billionaires
GlobeNewswire
20 days ago
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors
TipRanks
25 days ago
Goldman Sachs Says It’s Time to Pull the Trigger on Healthcare Stocks — Here Are 2 Names to Pounce on Now
TipRanks
a month ago
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
MT Newswires
a month ago
B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236
MT Newswires
a month ago
Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.